Ceasing to be a substantial holder
Released
Released
Announcement PDF
605
Page 1 of 2
Form 605
Corporations Act 2001
Section 671B
Notice of ceasing to be a substantial holder
To Company Name/Scheme
ALTERITY THERAPEUTICS LTD
ACN/ARSN/ABN
37 080 699 065
1. Details of substantial holder (1)
Name
JPMorgan Chase & Co. and its affiliates
ACN/ARSN (if applicable)
NA
The holder ceased to be a substantial holder on
03/05/2024
The previous notice was given to the company on
06/03/2024
The previous notice was dated
04/03/2024
2.
Changes in relevant interests
Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company
or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:
Person whose relevant
interest changed
Date of
change
See
Appendix
See
Appendix
See
Appendix
Nature of change (4)
Consideration given
in relation to change
(5)
Class (6) and
number of
securities affected
See Appendix
4,860,000
(Ordinary)
4,860,000
(Ordinary)
Person's
votes
affected
J.P. MORGAN
SECURITIES LLC
Holder of securities subject to an
obligation to return under a securities
lending agreement
J.P. MORGAN
SECURITIES LLC
Rehypothecation of client securities
under a Prime Brokerage Agreement
See Appendix
137,400
(Ordinary)
137,400
(Ordinary)
J.P. MORGAN
SECURITIES
AUSTRALIA
LIMITED
Purchase and sales of securities in its
capacity as Principal/Proprietary
See Appendix
240,000,000
(Ordinary)
240,000,000
(Ordinary)
3. Changes in association
The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the
relation to voting interests in the company or scheme are as follows:
Name and ACN/ARSN (if applicable)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
substantial holder in
Nature of association
Subsidiary of JPMorgan Chase & Co.
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES LLC
4. Addresses
The addresses of persons named in this form are as follows:
Name
Address
JPMorgan Chase & Co.
383 Madison Avenue, New York, New York, NY, 10179, United States
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
LEVEL 18, 83-85 CASTLEREAGH STREET, SYDNEY, NSW 2000, Australia
J.P. MORGAN SECURITIES LLC
383 Madison Ave., New York, New York, NY, 10179, United States
Signature
Print name
Sign here
Lokesh Kumar
Capacity
Compliance Officer
Date
07/05/2024
605
Page 2 of 2
DIRECTIONS
(1)
If there are a number of substantial holders with similar or related relevant interests (e.g. a corporation and its related corporations, or the manager and
trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they
may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly
set out in paragraph 4 of the form.
(2)
See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
(3)
See the definition of "associate" in section 9 of the Corporations Act 2001.
(4)
Include details of:
(a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of
any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract,
scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the
securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
(5)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may,
become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional n the happening or not of a contingency.
Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid
directly to the person from whom the relevant interest was acquired.
(6)
T he voting shares of a company constitute one class unless divided into separate classes.
(7)
Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
TRADES FOR RELEVANT PERIOD
Transaction Date
Balance at start of relevant period
3-May-24
3-May-24
3-May-24
3-May-24
Balance at end of relevant period
Entity
Product Type
Type of Transaction
J.P. MORGAN SECURITIES LLC
J.P. MORGAN SECURITIES LLC
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Equity - Depository Receipt
Equity - Depository Receipt
Equity
Equity
On-Lend
Borrow Return
Sell
Sell
Quantity
368,579,211
137,400
(4,860,000)
(150,000,000)
(90,000,000)
123,856,611
Appendix
Consideration
Price (AUD)
0.01
0.01
$
$
$
$
900,000.00
450,000.00
1/1
Share your feedback
Discover